InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | 2026-04-27 | BROADWOOD PARTNERS, L.P. | 10% Owner | Purchase | 250.9K | $3.64 | $913K | 12.68M | View ↗ | |
| 2026-04-24 | 2026-04-27 | BROADWOOD PARTNERS, L.P. | 10% Owner | Purchase | 38.9K | $3.53 | $137K | 12.43M | View ↗ | |
| 2026-04-23 | 2026-04-27 | BROADWOOD PARTNERS, L.P. | 10% Owner | Purchase | 280.4K | $3.50 | $982K | 12.40M | View ↗ | |
| 2026-04-20 | 2026-04-20 | BROADWOOD PARTNERS, L.P. | 10% Owner | Purchase | 40.7K | $3.88 | $158K | 12.11M | View ↗ | |
| 2026-04-17 | 2026-04-20 | BROADWOOD PARTNERS, L.P. | 10% Owner | Purchase | 40.1K | $3.57 | $143K | 12.07M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net revenue | $4.05B+115.6% | $1.88B+25.1% | $1.50B+156789.4% | $958K |
| Cost of revenues | $1.75B+66.2% | $1.05B+5.1% | $1.00B+113763.6% | $880K |
| Cost of revenues – amortization of acquired intangibles | $7.0M-92.0% | $88.0M+0.0% | $88.0M+91566.7% | $96K |
| Gross profit | $2.30B+210.5% | $740.0M+79.2% | $413.0M | — |
| Research and development | $15.90B+61.6% | $9.84B+5.9% | $9.29B+127197.6% | $7.3M |
| Sales and marketing | $6.34B+60.8% | $3.94B+41.1% | $2.79B+246808.1% | $1.1M |
| General and administrative | $10.63B+4.2% | $10.20B-8.7% | $11.18B+51003.7% | $21.9M |
| Change in fair value of contingent consideration | $5.95B+239.1% | -$4.28B+25.8% | -$5.76B-18475.7% | -$31.0M |
| Impairment losses | $14.60B-65.2% | $41.90B+520.1% | $6.76B | — |
| Impairment loss on held for sale assets | $0-100.0% | $169.0M-86.8% | $1.28B | — |
| Total operating expenses | $53.42B-13.5% | $61.78B+141.8% | $25.55B+142004.7% | $18.0M |
| Loss from operations | -$51.12B+16.2% | -$61.04B-142.8% | -$25.14B-139567.7% | -$18.0M |
| Interest expense | -$109.0M-29.8% | -$84.0M-61.5% | -$52.0M-62550.6% | -$83K |
| Other income, net | $1.01B+118.8% | $462.0M+17.3% | $394.0M | — |
| Total other income, net | $902.0M+138.6% | $378.0M+34.5% | $281.0M | — |
| Loss before income taxes | -$50.22B+17.2% | -$60.66B | — | — |
| Income taxes | $0 | $0 | — | — |
| Net loss | -$50.22B+17.2% | -$60.66B-118.4% | -$27.78B-38007.3% | -$72.9M |
| Net loss attributable to common stockholders - basic | -$50.22B+17.6% | -$60.93B-112.1% | -$28.72B | — |
| Net loss attributable to common stockholders - diluted | -$50.22B+17.6% | -$60.93B-112.1% | -$28.72B | — |
| Net loss attributable to common stockholders per share - basic | -$2K+64.6% | -$5K-24.3% | -$4K | — |
| Net loss attributable to common stockholders per share - diluted | -$2K+64.6% | -$5K-24.3% | -$4K | — |
| Weighted average shares outstanding - basic | $30.5M+133.2% | $13.1M+70.8% | $7.7M | — |
| Weighted average shares outstanding - diluted | $30.5M+133.2% | $13.1M+70.8% | $7.7M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
iMDx to Release First Quarter 2026 Results on May 13, 2026
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx Milestones
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay
Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst